Dr. Gold is an accomplished clinical research specialist with special interests in acute leukemia’s brain tumors and late effects of cancer therapy. Gold heads a comprehensive brain tumor clinic that meets monthly. This clinic brings together experts from the disciplines of neurology, neurosurgery, radiology, psychology and sociology. Patients receive comprehensive, multidisciplinary evaluation, treatment planning and therapy. Gold also runs a monthly clinic in Wilmington and Raleigh that serves the pediatric oncology needs of those communities.
In addition to these responsibilities, Dr. Gold serves on multiple important cancer committees. Dr. Gold is a member of several key committees and treatment protocol committees in the Children’s Cancer Group (CCG). The CCG is the largest group of Pediatric Cancer institutions in the world, which pools its resources and patients to advance the treatment outcomes for children with cancer. Dr. Gold also serves on several state committees and is an officer of the board of the Chapel Hill Ronald McDonald House.
Education and Training
BA, Vanderbilt University
MD, Vanderbilt University
Residency and Internship, Pediatrics, University of Colorado Health Sciences Center
Fellowship, Pediatric Hematology-Oncology, University of Colorado Health Sciences Center
Research
Dr. Gold’s research interests include integrative medicine, long-term survivorship issues, improving medical outcomes for children with cancer, particularly leukemia and lymphoma, addressing barriers to care, and palliative care. Dr. Gold’s research initiatives have included:
- The development of pediatric self- and proxy-reported outcome measures to inform symptom monitoring and adverse event reporting for children enrolled in cancer clinical trials.
- Site Principal Investigator for UNC within the Children’s Oncology Group, for which over 50 studies are open at UNC.
- In collaboration with investigators at Duke University, principal investigator of a phase I trial of an ara-G analogue for recurrent leukemia and lymphoma. He also continues laboratory investigations into gene amplification, particularly the ability of normal T and B-lymphocytes to amplify the CAD gene in leukemia.
